First Commercial Volume Printing Equipment OrganSEC Released in China

TapTechNews August 27th news, the first Green Key Volume Printing Technology Application Forum was held yesterday at the Panyu Campus of Guangzhou Medical University. Guangzhou Medical University, in conjunction with relevant units, released the first commercial volume printing equipment OrganSEC in China.

First Commercial Volume Printing Equipment OrganSEC Released in China_0

OrganSEC adopts the back-projection algorithm based on holographic imaging projection technology and CT imaging principle. This technology can project the two-dimensional slices of a three-dimensional object into a printing bottle that rotates at a certain speed through a specific algorithm, enabling the photocurable ink in the printing bottle to form a three-dimensional object simultaneously in all directions. This technology solves the problems of slow printing speed and low cell survival rate in conventional layer-by-layer printing, and its technical indicators reach the international first-class level, filling the domestic gap.

First Commercial Volume Printing Equipment OrganSEC Released in China_1

TapTechNews attaches the following advantages of OrganSEC:

Ultra-fast printing: Complete the printing of centimeter-sized three-dimensional (active) structures within 10-120 seconds

High cell activity: The cell survival rate after printing is > 95%

High-resolution printing: The printing resolution reaches 50 microns

The printing system has no contact with the printed object and causes no physical damage to the cells

The surface of the printed object is smooth, truly simulating the surface structure of organs

Sterile printing

Moderate printing conditions: Printing can be achieved at room temperature using visible light, which is more suitable for biological printing

It is introduced that OrganSEC will mainly target the organoid market, including organoid preparation, tumor personalized drug use based on organoids, and drug screening based on organoids, to provide accurate personalized drug guidance for tumor patients.

Likes